Examining Best Practices for Specialty Pharmacists to Improve the Care of Patients With α1-Antitrypsin Deficiency
This continuing education activity is supported by an educational grant from CSL Behring.
THIS ACTIVITY IS SUPPORTED BY AN EDUCATIONAL GRANT FROM CSL BEHRING.
Mark A. Malesker, PharmD, FCCP, FCCM, FASHP, BCPS, Professor of Pharmacy Practice and Medicine at Creighton University in Omaha, Nebraska
Lee E. Morrow, MD, FCCP, ATF, MSc, Professor of Medicine in the Division of Pulmonary and Critical Care at Creighton University, Chief of Pulmonary and Critical Care at Nebrasks-Western Iowa VA Medical Center in Omaha, Nebrasksa
At the completion of this activity, the participant will be able to:
- Explain the hereditary basis, pathophysiology, and diagnostic challenges of α₁-antitrypsin deficiency (AATD)
- Investigate the available therapies for AATD by understanding key characteristics including mechanism of action and efficacy
- Examine the dosing, preparation, and administration of available therapies for AATD
- Identify key counseling points for effective communication with patients receiving augmentation therapy for AATD
TARGET AUDIENCE: Pharmacists
RELEASE DATE: December 20, 2019
EXPIRATION DATE: June 15, 2021
ESTIMATED TIME TO COMPLETE ACTIVITY: 2 hours
FEE: This lesson is offered for free at www.pharmacytimes.org.